Biomedical Occupation or Discipline – Page 6

Novartis Bets on Covalent Chemistry in $1B Matchpoint Therapeutics Deal

3 months ago talkbio0Tagged Advanced phase, biotechnology partnerships, covalent chemistry, Covalent Interaction, Drug Development, Inflammatory disorder, License, Matchpoint Therapeutics, Novartis, oral inhibitors

Novartis; Matchpoint Therapeutics; covalent chemistry; exclusive option and license agreement; inflammatory diseases; oral inhibitors; Advanced Covalent Exploration platform; drug development; biotechnology partnerships

Biogen Pledges $2 Billion Manufacturing Investment in North Carolina

3 months ago talkbio0Tagged Antisense Oligonucleotides, Artificial Intelligence, Automation, Biogen, Biotechnology, expansion, gene therapy, Investments, Manufacturing, North Carolina, Research Triangle Park

Biogen; manufacturing investment; North Carolina; Research Triangle Park; biotechnology; antisense oligonucleotides; gene therapy; automation; AI; expansion

Viatris Ophthalmic Drug Fails Phase 3 for Blepharitis; Company Weighs Next Steps

3 months ago talkbio0Tagged Blepharitis, Clinical trial failure, Drug Development, MR-139, ophthalmic preparation, Phase 3 Clinical Trials, pimecrolimus, pipeline, strategic review, Viatris

Viatris; ophthalmic drug; Phase 3 study; blepharitis; MR-139; clinical trial failure; drug development; pimecrolimus; pipeline; strategic review

Kowa Secures Expanded Rights to Nicox’s Glaucoma Drug NCX 470 in Major Global Deal

3 months ago talkbio0Tagged Clinical Trials, Denali, Glaucoma, Kowa, licensing agreement, milestone payments, naproxen-n-butyl nitrate, Ophthalmology specialty, royalties, TLX2 gene

Kowa; Nicox; NCX 470; glaucoma; exclusive rights; licensing agreement; Denali clinical trial; ophthalmology; royalties; milestone payments

Pfizer Warns of ‘Near-Term Stock Out’ of Penicillin Used for Treating Syphilis in Pregnant Women After Recall

3 months ago talkbio0Tagged Bicillin L-A, Drug Shortage, Extencilline, penicillin recall, Pfizer, Pregnant Women, public health medicine (field), syphilis treatment, Syphilis, Congenital, United States Food and Drug Administration

Pfizer; penicillin recall; Bicillin L-A; syphilis treatment; pregnant women; drug shortage; congenital syphilis; FDA; Extencilline; public health

AstraZeneca Amyloidosis Drug Fails Phase 3 Trials but Shows Potential in Subgroup

3 months ago talkbio0Tagged Alexion, Amyloidosis, Anselamimab, AstraZeneca, Clinical trial failure, Drug Development, Infrequent, prespecified, Primary amyloidosis, Subgroup A Nepoviruses

AstraZeneca; amyloidosis; anselamimab; Phase 3 trial; clinical trial failure; prespecified subgroup; rare diseases; Alexion; AL amyloidosis; drug development

Advancements in Predicting Tumor Response and Expanding Therapy Eligibility Using Epigenomic Biomarkers

3 months ago talkbio0Tagged Biological Markers, Diagnostics, DNA Methylation, Epigenomics, personalized cancer therapy, Prediction, tumor response

epigenomic biomarkers; tumor response prediction; personalized cancer therapy; DNA methylation; AI-driven diagnostics

LEO Pharma Acquires Exclusive Global Rights for Boehringer Ingelheim’s Psoriasis Drug Spevigo in €90 Million Deal

3 months ago talkbio0Tagged Boehringer Ingelheim, Drug licensing, Generalized pustular psoriasis, IL1RAP protein, human, Immunology, News [Publication Type], Partnership, Pharma, Psoriasis, spesolimab, Spevigo

LEO Pharma; Boehringer Ingelheim; Spevigo; spesolimab; psoriasis; GPP; drug licensing; immunology; IL-36 receptor; partnership; biotech news

GSK’s ViiV Expands Licensing Deal to Increase Access to Long-Acting Injectable HIV Treatment

3 months ago talkbio0Tagged cabotegravir, Environmental pool, generic manufacturing, Global Health, HIV, licensing agreement, SmithKline Beecham, ViiV Healthcare

GSK; ViiV Healthcare; long-acting HIV treatment; cabotegravir; licensing agreement; Medicines Patent Pool; generic manufacturing; HIV; global health

NUCLIDIUM Sees Copper Isotopes as Future of Radiopharmaceuticals, Raises CHF 79M to Advance Clinical Development

3 months ago talkbio0Tagged cancer diagnostics, cancer therapeutics, copper isotopes, Malignant neoplasm of breast, Metastatic Prostate Carcinoma, Neoplasms, Neuroendocrine Tumors, NUCLIDIUM, NuriPro, Radiopharmaceuticals, Series B financing, Theranostics, TraceNET

NUCLIDIUM; copper isotopes; radiopharmaceuticals; Series B financing; Cu-NuriPro; NuriPro; TraceNET; oncology; theranostics; metastatic prostate cancer; neuroendocrine tumors; breast cancer; cancer diagnostics; cancer therapeutics